In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor

Area of Science:

• Microbiology
• Medicinal Chemistry
• Pharmacology

Background:

• Tuberculosis (TB) remains a global health challenge, driven by drug-resistant strains.
• Novel therapeutic agents are urgently needed to combat multidrug-resistant TB (MDR-TB).
• Transitmycin (TR) is a newly identified secondary metabolite from Streptomyces sp. with potential anti-TB activity.

Purpose of the Study:

• To evaluate the in vitro and in vivo anti-TB potency of Transitmycin (TR).
• To assess the in vivo safety profile of TR in animal models.
• To design and propose a safer analogue of TR with improved therapeutic potential.

Main Methods:

• In vitro testing of TR against 49 drug-resistant TB clinical isolates.
• In vivo safety and efficacy studies in mice, rats, and guinea pigs at varying doses.
• In silico molecular design, including detoxification approaches and structure-activity relationship (SAR) analysis, to create TR analogues.

Main Results:

• TR demonstrated significant in vitro activity, inhibiting 94% of drug-resistant TB strains at 10μg/mL.
• In vivo studies revealed toxicity at 0.005mg/kg but safety at 0.001mg/kg, though the latter did not reduce infection load.
• TR acts as a DNA intercalator and targets Mycobacterium RecA and methionine aminopeptidases.
• Analogue 47 was designed with proposed reduced toxicity and non-DNA intercalating properties.

Conclusions:

• Transitmycin exhibits potent in vitro activity against drug-resistant TB but shows significant in vivo toxicity.
• The development of TR analogues, such as Analogue 47, using in silico methods offers a promising strategy to overcome parental compound toxicity.
• Further laboratory validation is required to confirm the therapeutic potential of TR analogues as novel anti-TB agents.